Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 8, 1999 - Issue 10
Submit an article Journal homepage
27
Views
2
CrossRef citations to date
0
Altmetric
Review

Therapeutic advances in idiopathic Parkinsonism

Sandra Lynne Shefrin Neurodegenerative Disorders Centre, Faculty of Medicine, Division of Neurology, Vancouver Hospital and Health Sciences Centre, Purdy Pavilion, 2211 Westbrook Mall, University of British Columbia, Vancouver, BC, Canada V6T 2B5. [email protected]
Pages 1565-1588 | Published online: 23 Feb 2005

Bibliography

  • EHRINGER H, HORNYKIEWICZ 0: Verteilung von noradrenalin und dopamin (3-Hydroxytyramin)im Gehirn des Menschen und. Kiln. Woch. (1960) 38:1236–1239.
  • SANO I: Biochemistry of the extrapyramidal system. Prog. Neurol Sci. (1960) 5:42–48.
  • TOLOSA E, MARTI MJ, VALLDEORIOLA F, MOLINUEVO JL: History of levodopa and dopamine agonists in Parkin-son's disease treatment. Neurology (1998) 50\(Suppl. 6):S2–S10.
  • KOLLER WC, RUEDA MG: Mechanism of action ofdopaminergic agents in Parkinson's disease. Neurology (1998) 50\(Suppl. 6):S11–S14.
  • BIRKMAYER W, HORNYKIEWICZ 0: Der L-Dioxyphenylalanin. Wien. Kiln. Wochenschr. (1961) 73:787–788.
  • COTZIAS GC, VAN WOERT MH, SCHIFFER LM: Aromatic amino acids and modification of parkinsonism. New Engl. J. (1967) 276:374–379.
  • CALNE DB. TEYCHENNE PF. LEIGH PN. BAMJI AN. GREENACRE JK: Treatment of parkinsonism with bromocriptine. Lancet (1974) 2:1355–1356.
  • KURTH MC. ADLER CH: COMT inhibition: a new treatment strategy for Parkinson's disease. Neurology (1998) 50\(Suppl. 5):S3–14.
  • PARKINSON'S STUDY GROUP: Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl. J. Med. (1989) 321:1364–1367.
  • SAMII A, LETWIN SR, CALNE DB: Prospects for new drug treatment in idiopathic parkinsonism. Ther. Focus (1998) 3:131–140.
  • LANG AE, LOZANO AM: Parkinson's disease. N Engl. J. Merl. (1998) 339:1132–1143.
  • MELAMED E, OFFEN D, SHIRVAN A, DIALDETTI R, BARZILAI A, ZIV I: Levodopa toxicity and apoptosis. Ann. Neurol (1998) 44:S149–S154.
  • HORNE MK, CHENG CH, WOOTEN FG: The cerebral metabolism of L-Dihydroxyphenylalanine. Pharma-cology (1984) 28:12–26.
  • HORNYKIEWICZ 0: The mechanism of action of L-dopa in Parkinson's disease. Life Sci. (1974) 15:1249–1259
  • FAHN S: Welcome news about levodopa, but uncertainty remains. Ann. Neurol. (1998) 43:551–554.
  • RODRIGUEZ MC. OBESO JA. OLANOW CW: Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol (1998) 44( Suppl. 1):S175–88.
  • SAGE JI. MARK MH: The rationale for continuous dopaminergic stimulation in patients with Parkin-son's disease. Neurology (1992) 42(Suppl.
  • QUINN N. MARSDEN CD. PARKES JD: Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet (1982) 2(8295):412–5.
  • CAPILDEO R: Implications of the 5-year CR FIRST trial. Sinemet CR five-year international response fluctua-tion study. Neurology (1998) 50\(Suppl. 6):S15–517.
  • TANAKA M, SOTOMATSU A, KANAI H, HIRAI S: Dopa and dopamine cause cultured neuronal death in the presence of iron. J. Neurol. Sci. (1991) 101:198–203.
  • WICK MM, BYERS L, FREI E: L-Dopa: selective toxicity for melanoma cells in vitro. Science (1977) 197:468–469.
  • YOSHIKUNI M, IKEBA S, HATTORI N et al.: Etiology of Parkinson's disease. In: Movement Disorders, Neurologic Principles and Practice. Watts RL, Koller WC (Eds.), McGraw-Hill, New York (1997):161–183.
  • JENNER P, DEXTER DT, SIAN J, SCHAPIRA AHV, MARSDEN CD: Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann. Neurol. (1992) 32:S82–S87.
  • PRZEDBORSKI S, JACKSON-LEWIS V, MUTHANE U et al: Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann. Neurol (1993) 34(5):715–723.
  • SPENCER JP, JENNER A, ARUMOA OI, MARSDEN CD, HALLIWELL B: Intense oxidative DNA damage promoted by L-dopa and its metabolites: implications for neurodegenerative disease. FEBS Lett (1994) ?:246–250.
  • LI CL, WERNER P, COHEN G: Lipid peroxidation in brain: interactions of L-dopa/dopamine with ascorbate andiron. Neurodegeneration (1995) 4:147–153.
  • PARDO B, MENA MA, DE YEBENES JG: L-dopa inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells. Neurochem. (1995) 64:576–582.
  • PRZEDBORSKI S, JACKSON-LEWIS V, FAHN S: Antipark-insonian therapies and brain mitochondrial complex I activity. Mov. Disord. (1995) 10:312–317.
  • STEECE-COLLIER K, COLLIER TJ, SLADEK CD, SLADEK JRJR: Chronic levodopa impairs morphological development of grafted embryonic dopamine neurones. Exp. Neurol. (1990) 110(2):201–208.
  • OLANOW CW, JENNER P, BROOKS D: Dopamine agonists and neuroprotection in Parkinson's disease. Ann. Neurol (1998) 44\(Suppl. 1):S167–174.
  • WALKINSHAW G, WATERS CM: Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA: Implica-tions for the treatment of Parkinson's disease. J. Clin. Invest. (1995) 95(6):2458–2464.
  • FUKUDA T, WATABE K, TANAKA J: Effects of bromocriptine and/or L-DOPA on neurones in substantia nigra of MPTP-treated C57BL/6 mice. Brain Res. (1996) 728(2):274–276.
  • BLUNT SB, JENNER P, MARSDEN CD: Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov. Disord. (1993) 8(2):129–133.
  • MURER MG, DZIEWCZAPOLSKI G, MENALLED LB et al: Chronic levodopa is not toxic for remaining dopamine neurones, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol (1998) 43(5):561–575.
  • HAN SK, MYTILINEOU C, COHEN G: L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J. Neurochem. (1996) 66(2):501–510.
  • MYTILINEOU C, HAN SK, COHEN G: Toxic and protec-tive effects of L-dopa on mesencephalic cell cultures. J. Neurochem. (1993) 61(4):1470–1478.
  • MENA MA, DAVILA V, SULZER D: Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. j Neurochem. (1997) 69(4):1398–1408.
  • CALNE DB: The free radical hypothesis in idiopathic parkinsonism: evidence against it. Ann. Neurol (1992) 32(6)799–803
  • RAJPUT AH, FENTON ME, BIRDI S, MACAULAY R: Is levodopa toxic to human substantia nigra? Mov. Disord. (1997) 12(5):634–638.
  • MENA MA, CASAREJOS MJ, CARAZO A, PAINO CL, GARCIA DE YEBENES J: Glia protect fetal midbrain dopamine neurones in culture from L-DOPA toxicity through multiple mechanisms. J. Neural Transm. (1997) 104(4–5)317–328.
  • RASCOL A, MONTASTRUC JL, GUIRAUD-CHAUMEIL B, CLANET M: Bromocriptine as the 1st treatment of Parkinson's disease. Long term results. Rev. Neurol. (1982) 138(5):401–408,.
  • POEWE W: Adjuncts to levodopa therapy: dopamine agonists. Neurology (1998) 50\(Suppl. 6):S23–S26.
  • YAMAMOTO M: Do dopamine agonists provide neuroprotection?Neurology (1998) 51 (Suppl. 2):S10–S12.
  • OGAWA N: Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease. Neurology (1998) 51\(Suppl. 2):S13–S20.
  • ROBERTSON GS, ROBERTSON HA: Synergistic effects of D(1) and D(2) dopamine agonists on turning behaviour in rats. Brain Res. (1986) 384:387–390.
  • GRONDIN R, DOAN VD, GREGOIRE L, BEDARD PJ: DI receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology (1999) 52(4)771–776.
  • LEES AJ: Dopamine agonists in Parkinson's disease; a look at apomorphine. Fund. Clin. Pharmacol. (1993) 7(3–4):121'–128.
  • ONDO W, HUNTER C, ALMAGUER M, GANCHER S, JANKOVIC J: Efficacy and tolerability of a novel sublin-gual apomorphine preparation in patients with fluctu-ating Parkinson's disease. Clin. Neuropharmacol. (1999) 22:1–4.
  • JANKOVIC J: New and emerging therapies for Parkin-son's disease. Arch. Neurol. (1999) 56:785–790.
  • HUTTON JT, CHASE T, VERHAGEN L et al.: Transdermal Dopamine D2 receptor agonist therapy with N-0923 TDS in Parkinson's disease (PD): a double-blind, placebo-controlled study. Mov. Disord. (1998) 13\(Suppl. 2):62.
  • MONTASTRUC JL, RASCOL 0, SENARD JM, RASCOL A: A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J. Neurol. Neurosurg. Psychiatry (1994) 57(9):1034–1038.
  • HELY MA, MORRIS JG, REID WG et al.: The Sydney Multicentre Study of Parkinson's disease: a random-ised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J. Neurol. Neurosurg. Psychiatry (1994) 57(8):903–910.
  • RINNE UK: Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology (1987) 37(5):826–828.
  • GIMENEZ-ROLDAN S, TOLOSA E, BURGUERA JA, CHACON J, LIANO H, FORCADELL F: Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clin. Neuropharmacol. (1997) 20(1):67–76.
  • WOOTEN GF: Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease. Ann. Neurol (1988) 24(3)363–365.
  • FACTOR SA, WEINER WJ: Early combination therapy with bromocrptine and levodopa in Parkinson's disease. Mov. Disord. (1993) 8:257–262.
  • SHANNON KM, BENNETT JP JR, FRIEDMAN JH: Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology (1997) 49(3):724–728.
  • RASCOL 0, BROOKS DJ, KORCZYN AD ON BEHALF OF THE 056 STUDY GROUP: Ropinerole reduces risk of dyskinesia when used in early PD. Park. Related Disord. Abstracts of the XIII International Congress on Parkinson's disease. Vancouver, Canada (1999):S83.
  • SETHY VH, WU H, OOSTVEEN JA, HALL ED: Neuropro-tective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res. (1997) 754:181–186.
  • GASSEN M, PINCHASI B, YOUDIM MB: Apomorphine is apotent radical scavenger and protects cultured pheochromocytoma cells from 6-0HDA and 11202-induced cell death. Adv. Pharmacol. (1998) 42:320–324.
  • FELTEN DL, FELTEN SY, FULLER RW et al: Chronicdietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats. Neurobiol. Aging (1992) 13(2):339–351.
  • MARTTILA RJ, RINNE UK: Disability and progression inParkinson's disease. Acta Neurol. Scand. (1977) 56(2):159–69.
  • MARTINEZ-MARTIN P, O'BRIEN CF: Extending levodopaaction: COMT inhibition. Neurology (1998) 50\(Suppl. 6):S27–32.
  • PEPPE A, DAMBROSIA JM, CHASE TN: Risk factors formotor response complications in L-dopa-treated parkinsonian patients. Adv. Neurology (1 99 3) 60:698–702.
  • DAPRADA M, ZURDHER G, KETTLER R, DINGEMANSE H,JORGA K, DUBUIS R: Remodeling the kinetics of dynamics of levodopa therapy in Parkinson's disease by inhibiting MAO-B with lazabemide and COMT with tolcapone. In: Levodopa-the first 25 years. Poewe W, Lees AJ (Eds.) Basel: Editions Roche (1993):99–117.
  • NISSINEN E, LINDEN IB, SCHULTZ E, POHTO P:Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn-Schmiedebergs Arch. Pharmacol. (1992) 346(3):262–266.
  • MANNISTO PT: Clinical potential of catechol-0-methyl-transferase (COMT) inhibitors as adjuvants in Parkinson's disease. CNS Drugs (1994) 1:172–179.
  • RUOTTINEN HM, RINNE UK: Entacapone prolongs levodopa response in a one month double blind study in Parkinsonian patients with levodopa related fluctuations. J. Neurol. Neurosurg. Psychiatry (1996) 60:36–40.
  • KIEBURTZ K, COMTAN BF: Safety and efficacy profile ofa new COMT inhibitor, clinical efficacy review. Abstract of the satellite symposium organised by Novartis Pharma AG. XIII International Congress on Parkinson's disease. Vancouver, Canada. (1999):8.
  • WATERS CH, KURTH M, BAILEY P et al.: Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology (1997) 49:665–671.
  • OBESO JA, RODRIGUEZ MC, DELONG MR: Basal ganglia pathophysiology. A critical review. Adv. Neurology (1997) 74:3–18.
  • HOLLMANN M, HEINEMANN S: Cloned glutamate receptors. Ann. Rev. Neurosci. (1994) 17:31–108.
  • STANDAERT DG, TESTA CM, YOUNG AB, PENNEY JB JR:Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J. Comp. Neurol. (1994) 343(1):1–16.
  • GURIDI J, HERRERO MT, LUQUIN MR et al.: Subthala-motomy in parkinsonian monkeys. Behavioural and biochemical analysis. Brain (1996) 119:1717–1727.
  • BERGMAN H, WICHMANN T, KARMON B, DELONG MR:The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol (1994) 72(2):507–520.
  • POLLAK P, BENABID AL, LIMOUSIN P, BENAZZOUZ A: Chronic intracerebral stimulation in Parkinson's disease. Adv. Neurol. (1997) 74:213–220.
  • LIMOUSIN P, GREENE J, POLLAK P, ROTHWELL J, BENABID AL, FRACKOWIAK R Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease. Ann. Neurol. (1997) 42(3):283–291.
  • FILION M, TREMBLAY L: Abnormal spontaneous activityof globus pallidus neurones in monkeys with MPTP-induced parkinsonism. Brain Res. (1991) 547 (1):142–151.
  • LEIGH PN, MELDRUM BS: Excitotoxicity in ALS.Neurology (1996) 47 (Suppl. 4):S221–S227.
  • MARCHETTI P, CASTEDO M, SUSIN SA et al. Mitochon- drial permeability transition is a central coordinating event of apoptosis. J. Exp. Med. (1996) 184(3) 1155–1160
  • MATTSON MP, ZHANG Y, BOSE S: Growth factors prevent mitochondrial dysfunction, loss of calcium homeostasis, and cell injury, but not ATP depletion in hippocampal neurones deprived of glucose. Exp. Neurol. (1993) 12 1 (1):1–13.
  • PRZEDBORSKI S, JACKSON-LEWIS V, YOKOYAMA R, SHIBATA T, DAWSON VL, DAWSON TM: Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTI) -induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. USA (1996) 93(10):4565–4571.
  • BECKMAN JS, BECKMAN TW, CHEN J, MARSHALL PA, FREEMAN BA: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA (1990) 87(4):1620–1624.
  • ISCHIROPOULOS H, ZHU L, CHEN J et al: Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. (1 9 9 2) 298(2):431–437.
  • NAKAO N, FRODL EM, WIDNER H et al.: OverexpressingCu/Zn superoxide dismutase enhances survival of transplanted neurones in a rat model of Parkinson's disease. Nature Med. (1995) 1(3)226–231.
  • ZHANG J, DAWSON VL, DAWSON TM, SNYDER SH: Nitricoxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science (1994) 263(5147):687–689.
  • ORRENIUS S, BURKITT MJ, KASS GE, DYPBUKT JM, NICOTERA P: Calcium ions and oxidative cell injury. Ann. Neurology (1992) 32(Suppl):533–542.
  • NOVELLI A, REILLY JA, LYSKO PG, HENNEBERRY RC: Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. (1988) 451(1-2):205–212.
  • MAREY-SEMPER I, GELMAN M, LEVI-STRAUSS M: A selective toxicity toward cultured mesencephalic dopaminergic neurones is induced by the synergistic effects of energetic metabolism impairment and NMDA receptor activation. J. Neurosci. (1995) 15 (9):5912–5918.
  • SHINOTOH H, VINGERHOETS FJ, LEE CS et al.: Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study. Neurology (1997) 48(5):1282–1285.
  • JONES-HUMBLE SA, MORGAN PF, COOPER BR:The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson's disease. Life ScL (1994) 54(4):245–252.
  • BOIREAU A, DUBEDAT P, BORDIER F et al.: Riluzole andexperimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. Neuroreport (1994) 5(18):2657–2660.
  • BARNEOUD P, MAZADIER M, MIQUET JM et al.: Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. Neuroscience (1996) 74 (4):971–983.
  • TURSKI L, BRESSLER K, RETTIG KJ, LOSCHMANN PA,WACHTEL H: Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature (1991) 349(6308):414–418.
  • ZUDDAS A, OBERTO G, VAGLINI F, FASCETTI F, FORNAIF, CORSINI GU: MK-801 prevents 1-methy1-4-pheny1-1,2,3,6-tetrahydropyridine-induced parkin-sonism in primates. J. Neurochem. (1992) 59(2)733–739.
  • SONSALLA PK, ZEEVALK GD, MANZINO L et al: MK-801 fails to protect against the dopaminergic neuropa-thology produced by systemic 1-methy1-4-pheny1-1,2,3,6-tetrahydropyridine in mice or intrani-gral 1-methyl-r-phenylpyridium in rats. J. Neurochem. (1992) 58:1979–1982.
  • GOETZ CG: New lessons from old drugs: amantadine andParkinson's disease. Neurology (1 9 9 8)50(5):1211–1212.
  • WOOTEN GF: Neurochemistry and neuropharma-cology of Parkinson's disease. In: Movement Disorders, Neurologic Principles and Practice. Watts RL, Koller WC (Eds.) McGraw-Hill, New York (1997):153–160.
  • LLOYD KG, HORNYKIEWICZ 0: L-glutamic acid decarboxylase in Parkinson's disease: effect of L-dopa therapy. Nature (1973) 243(5409):521–523.
  • CILIAX BJ, GREENAMYRE JT, LEVEY Al: Functional biochemistry and molecular neuropharmacology of the basal ganglia and motor systems. In: Movement Disorders, Neurologic Principles and Practice. Watts RL, Koller WC (Eds.), McGraw-Hill, New York (1997):99–116.
  • SCHNEIDER JS, VAN VELSON M, MENZAGHI F, LLOYD GK: Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. Ann. Neurol (1998) 43(3):311–317.
  • PAULUS W, JELLINGER K: The neuropathologic basis of different clinical subgroups of Parkinson's disease. J. Neuropathol. Exp. Neurol. (1991) 50(6):743–755.
  • KUHL DE, MINOSHIMA S, FESSLER JA et al.: In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann. Neurol. (1996) 40(3):399–410.
  • SHULTS CW: Neurotrophic factors. In: Movement Disorders, Neurologic Principles and Practice. Watts RL, Koller WC (Eds.), McGraw-Hill, New York (1997):117–124.
  • GASH DM, ZHANG Z, GERHARDT G: Neuroprotective and neurorestorative properties of GDNF. Ann. Neurol 44 (Suppl. 1):S121–S125.
  • TOMAC A. LINDQVIST E. LIN LF et al.: Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature (1995) 373(6512):335–339.
  • LAPCHAK PA, MILLER PJ, COLLINS F, RAO S: Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neurosci-ence (1997) 78(0:61–72.
  • MIYOSHI Y, ZHANG Z, OVADIA A et al.: Glial cell line-derived neurotrophic factor-levodopa interac-tions and reduction of side effects in parkinsonian monkeys. Ann. Neurol (1997) 42(2):208–214.
  • TSENG JL, BAETGE EE, ZURN AD, AEBISCHER P: GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. J. Neurosci. (1997) 17 (1):325–333.
  • BILANG-BLEUEL A, REVAH F, COLIN P: Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopamin-ergic neuron degeneration and behavioral impair-ment in a rat model of Parkinson's disease. Proc. Natl. Acad. ScL USA (1997) 94(16):8818–8823.
  • GRONDIN R, BEDARD PJ, HADJ TAHAR A, GREGOIRE L, MORI A, KASE H: Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology (1 9 9 9) 52 (8):1673–1677.
  • PETERFREUND RA, MACCOLLIN M, GUSELLA J, FINK JS: Characterization and expression of the human A2A adenosine receptor gene. J. Neurochem. (1996) 66(1)362-368. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(10)
  • VAN CALKER D, MULLER M, HAMPRECHT B: Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. (1979) 33 (5) :999–1005.
  • MARTINEZ-MIR MI, PROBST A, PALACIOS JM: Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. Neuroscience (1991) 42(3):697–706.
  • KANDA T, JACKSON MJ, SMITH LA et al.: Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol (1998) 43(4):507–513.
  • FERRE S, FUXE K: Dopamine denervation leads to an increase in the intramembrane interaction between adenosine Ay and dopamine D2 receptors in the neostriatum. Brain Res. (1992) 594(0:124–130.
  • KEBABIAN JW, CALNE DB: Multiple receptors for dopamine. Nature (1979) 277(5692):93–96.
  • RAJPUT AH, UITTI RJ, OFFORD KP: Timely levodopa (LD) administration prolongs survival in Parkinson's disease. Parkinsonism Relat. Disord. (1997) 3:159–65.
  • MARTIN JB: Mechanisms of Disease: molecular basis of the neurodegenerative disorders. New Engl. J. Med. (1999) 340:1970–1980.
  • GASSER T, MULLER-MYHSOK B, WSZOLEK ZK et al: A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nature Genet. (1998) 18(3):262–265.

Websites

  • http://iddb.com:80/idintranet/p1sql/Rpt RHONE-POULENC SA: Riluzole [Drug Report]. (22/06/1999).
  • http://iddb.com:80/idintranet/p1sql/Rpt KYOWA HAKKO KOGYO CO. LTD.: KW-6002 [Drug Report]. (22/06/1999).
  • http://iddb.com:80/idintranet/p1sql/Rpt SIBIA NEUROSCIENCES, INC.: SIB-1508Y [Drug Report]. (22/06/1999).
  • http://iddb.com:80/idintranet/p1sql/Rpt AMGEN/MEDTRONIC AMGEN BOULDER, INC.: GDNF [Drug Report]. (22/06/1999).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.